Filing Flows › Neogenomics (NEO) › Guidance history
Neogenomics (NEO) guidance history: what it guided and what it reported
Neogenomics gave guidance in 9 earnings releases on file since Jul 29, 2024. Its releases raised guidance 5 times and lowered it 0 times.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $797M–$803M (Apr 28, 2026) | — | to be reported | — |
Adjusted revenue
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2024 | $655M–$667M (Jul 29, 2024) | — | — | — |
Adjusted EBITDA
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q4 2026 | $13.0M (Feb 17, 2026) | — | to be reported | — |
| Q4 2025 | $12.0M (Feb 18, 2025) | — | — | — |
| FY2024 | $33.0M–$37.0M (Jul 29, 2024) | — | — | — |
The latest quarter
Neogenomics, Q3 2026: revenue $209M (+11% year over year), operating margin -3.8%, net loss $7.5M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
Questions
Does Neogenomics beat its guidance?
Neogenomics gave guidance in 9 earnings releases on file since Jul 29, 2024. Its releases raised guidance 5 times and lowered it 0 times.
How often does Neogenomics raise guidance?
Its earnings releases raised guidance 5 times and lowered it 0 times since Jul 29, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.